Cargando…
Recent advances and emerging therapies in the non-surgical management of ulcerative colitis
The so-called “biologicals” (monoclonal antibodies to various inflammatory targets like tumor necrosis factor or integrins) have revolutionized the treatment of inflammatory bowel diseases. In ulcerative colitis, they have an established role in inducing remission in steroid-refractory disease and,...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081982/ https://www.ncbi.nlm.nih.gov/pubmed/30135722 http://dx.doi.org/10.12688/f1000research.15159.1 |
_version_ | 1783345742257061888 |
---|---|
author | Wehkamp, Jan Stange, Eduard F. |
author_facet | Wehkamp, Jan Stange, Eduard F. |
author_sort | Wehkamp, Jan |
collection | PubMed |
description | The so-called “biologicals” (monoclonal antibodies to various inflammatory targets like tumor necrosis factor or integrins) have revolutionized the treatment of inflammatory bowel diseases. In ulcerative colitis, they have an established role in inducing remission in steroid-refractory disease and, thereafter, maintaining remission with or without azathioprine. Nevertheless, their limitations are also obvious: lack of primary response or loss of response during maintenance as well as various, in part severe, side effects. The latter are less frequent in anti-integrin treatment, but efficacy, especially during induction, is delayed. New antibodies as well as small molecules have also demonstrated clinical efficacy and are soon to be licensed for ulcerative colitis. None of these novel drugs seems to be much more effective overall than the competition, but they provide new options in otherwise refractory patients. This increasing complexity requires new algorithms, but it is still premature to outline each drug’s role in future treatment paradigms. |
format | Online Article Text |
id | pubmed-6081982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-60819822018-08-21 Recent advances and emerging therapies in the non-surgical management of ulcerative colitis Wehkamp, Jan Stange, Eduard F. F1000Res Review The so-called “biologicals” (monoclonal antibodies to various inflammatory targets like tumor necrosis factor or integrins) have revolutionized the treatment of inflammatory bowel diseases. In ulcerative colitis, they have an established role in inducing remission in steroid-refractory disease and, thereafter, maintaining remission with or without azathioprine. Nevertheless, their limitations are also obvious: lack of primary response or loss of response during maintenance as well as various, in part severe, side effects. The latter are less frequent in anti-integrin treatment, but efficacy, especially during induction, is delayed. New antibodies as well as small molecules have also demonstrated clinical efficacy and are soon to be licensed for ulcerative colitis. None of these novel drugs seems to be much more effective overall than the competition, but they provide new options in otherwise refractory patients. This increasing complexity requires new algorithms, but it is still premature to outline each drug’s role in future treatment paradigms. F1000 Research Limited 2018-08-07 /pmc/articles/PMC6081982/ /pubmed/30135722 http://dx.doi.org/10.12688/f1000research.15159.1 Text en Copyright: © 2018 Wehkamp J and Stange EF http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Wehkamp, Jan Stange, Eduard F. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis |
title | Recent advances and emerging therapies in the non-surgical management of ulcerative colitis |
title_full | Recent advances and emerging therapies in the non-surgical management of ulcerative colitis |
title_fullStr | Recent advances and emerging therapies in the non-surgical management of ulcerative colitis |
title_full_unstemmed | Recent advances and emerging therapies in the non-surgical management of ulcerative colitis |
title_short | Recent advances and emerging therapies in the non-surgical management of ulcerative colitis |
title_sort | recent advances and emerging therapies in the non-surgical management of ulcerative colitis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081982/ https://www.ncbi.nlm.nih.gov/pubmed/30135722 http://dx.doi.org/10.12688/f1000research.15159.1 |
work_keys_str_mv | AT wehkampjan recentadvancesandemergingtherapiesinthenonsurgicalmanagementofulcerativecolitis AT stangeeduardf recentadvancesandemergingtherapiesinthenonsurgicalmanagementofulcerativecolitis |